Results from a Phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Authors
Category Primary study
Conference41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13-17; Orlando, FL, United States. Journal of Clinical Oncology
Year 2005
This article has no abstract
Epistemonikos ID: c96fc2368b4089c4b5e88684a5f2bccbe09e7fbb
First added on: Aug 30, 2018